Have a feature idea you'd love to see implemented?
Let us know!
CRNX Crinetics Pharmaceuticals Inc
Price (delayed)
$57.03
Market cap
$5.29B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.71
Enterprise value
$5.02B
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate,
Highlights
CRNX's equity has surged by 52% year-on-year
The quick ratio has increased by 17% YoY
The revenue has dropped by 78% year-on-year and by 25% since the previous quarter
CRNX's gross profit has plunged by 78% YoY and by 25% from the previous quarter
Key stats
What are the main financial stats of CRNX
Market
Valuations
Earnings
Shares outstanding
92.74M
Market cap
$5.29B
Enterprise value
$5.02B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.48
Price to sales (P/S)
4,396.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4,834.26
Revenue
$1.04M
EBIT
-$277.91M
EBITDA
-$272.58M
Free cash flow
-$203.56M
Per share
Balance sheet
Liquidity
EPS
-$3.71
Free cash flow per share
-$2.54
Book value per share
$10.41
Revenue per share
$0.01
TBVPS
$11.7
Total assets
$937.37M
Total liabilities
$104.39M
Debt
$52.54M
Equity
$832.98M
Working capital
$824.03M
Debt to equity
0.06
Current ratio
16.38
Quick ratio
16.13
Net debt/EBITDA
0.98
Margins
Efficiency
Dividend
EBITDA margin
-26,235.1%
Gross margin
100%
Net margin
-26,747.8%
Operating margin
-29,525.2%
Return on assets
-31.9%
Return on equity
-36.1%
Return on invested capital
-46%
Return on capital employed
-31.4%
Return on sales
-26,747.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRNX stock price
How has the Crinetics Pharmaceuticals stock price performed over time
Intraday
1.71%
1 week
-4.41%
1 month
-2.84%
1 year
90.48%
YTD
60.29%
QTD
11.6%
Financial performance
How have Crinetics Pharmaceuticals's revenue and profit performed over time
Revenue
$1.04M
Gross profit
$1.04M
Operating income
-$306.77M
Net income
-$277.91M
Gross margin
100%
Net margin
-26,747.8%
The revenue has dropped by 78% year-on-year and by 25% since the previous quarter
CRNX's gross profit has plunged by 78% YoY and by 25% from the previous quarter
CRNX's operating income is down by 48% YoY and by 10% from the previous quarter
The operating margin has contracted by 47% from the previous quarter
Growth
What is Crinetics Pharmaceuticals's growth rate over time
Valuation
What is Crinetics Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.48
P/S
4,396.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4,834.26
The company's EPS fell by 2.2% YoY
CRNX's equity has surged by 52% year-on-year
CRNX's P/B is 52% above its 5-year quarterly average of 3.6 and 27% above its last 4 quarters average of 4.3
The P/S is 102% above the last 4 quarters average of 2180.8
The revenue has dropped by 78% year-on-year and by 25% since the previous quarter
Efficiency
How efficient is Crinetics Pharmaceuticals business performance
The company's return on sales fell by 43% QoQ
The company's return on equity rose by 37% YoY and by 2.4% QoQ
The ROA has increased by 36% YoY
The return on invested capital rose by 27% year-on-year but it has declined by 2.7% since the previous quarter
Dividends
What is CRNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRNX.
Financial health
How did Crinetics Pharmaceuticals financials performed over time
The total assets rose by 46% year-on-year
The quick ratio has increased by 17% YoY
The debt is 94% smaller than the equity
CRNX's equity has surged by 52% year-on-year
CRNX's debt to equity is down by 40% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.